About: Generation of potent neutralizing human monoclonal antibodies against cytomegalovirus infection from immune B cells

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Generation of potent neutralizing human monoclonal antibodies against cytomegalovirus infection from immune B cells Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Generation of potent neutralizing human monoclonal antibodies against cytomegalovirus infection from immune B cells
Creator	Vicenzi, Elisa Buick, Richard Cassetta, Luca Falciola, Luca Funaro, Ada Garotta, Gianni Gribaudo, Giorgio Landolfo, Santo Lo Buono, Nicola Luganini, Anna Malavasi, Fabio Murphy, Marianne Ortolan, Erika
Source	Medline; PMC
abstract	BACKGROUND: Human monoclonal antibodies (mAbs) generated as a result of the immune response are likely to be the most effective therapeutic antibodies, particularly in the case of infectious diseases against which the immune response is protective. Human cytomegalovirus (HCMV) is an ubiquitous opportunistic virus that is the most serious pathogenic agent in transplant patients. The available therapeutic armamentarium (e.g. HCMV hyperimmune globulins or antivirals) is associated with severe side effects and the emergence of drug-resistant strains; therefore, neutralizing human mAb may be a decisive alternative in the prevention of primary and re-activated HCMV infections in these patients. RESULTS: The purpose of this study was to generate neutralizing mAb against HCMV from the immunological repertoire of immune donors. To this aim, we designed an efficient technology relying on two discrete and sequential steps: first, human B-lymphocytes are stimulated with TLR9-agonists and IL-2; second, after both additives are removed, the cells are infected with EBV. Using this strategy we obtained 29 clones secreting IgG neutralizing the HCMV infectivity; four among these were further characterized. All of the mAbs neutralize the infection in different combinations of HCMV strains and target cells, with a potency ~20 fold higher than that of the HCMV hyperimmune globulins, currently used in transplant recipients. Recombinant human monoclonal IgG1 suitable as a prophylactic or therapeutic tool in clinical applications has been generated. CONCLUSION: The technology described has proven to be more reproducible, efficient and rapid than previously reported techniques, and can be adopted at low overall costs by any cell biology laboratory for the development of fully human mAbs for immunotherapeutic uses.
has issue date	2008-11-12(xsd:dateTime)
bibo:doi	10.1186/1472-6750-8-85
bibo:pmid	19014469
has license	cc-by
sha1sum (hex)	90662d7dc7b09e018829ae2bc13e167b218931d8
schema:url	https://doi.org/10.1186/1472-6750-8-85
resource representing a document's title	Generation of potent neutralizing human monoclonal antibodies against cytomegalovirus infection from immune B cells
has PubMed Central identifier	PMC2631500
has PubMed identifier	19014469
schema:publication	BMC Biotechnol
resource representing a document's body	covid:90662d7dc7b09e018829ae2bc13e167b218931d8#body_text
is schema:about of	named entity 'GENERATION' named entity 'result' named entity 'effective' named entity 'cytomegalovirus' named entity 'human monoclonal antibodies' named entity 'THERAPEUTIC ANTIBODIES' named entity 'EFFECTIVE' named entity 'MONOCLONAL ANTIBODIES' named entity 'MONOCLONAL ANTIBODIES' named entity 'B CELLS' named entity 'IMMUNE' named entity 'INFECTIOUS DISEASES' named entity 'HUMAN' named entity 'BACKGROUND' named entity 'GENERATED' named entity 'AS A RESULT OF' named entity 'CASE' named entity 'HUMAN' named entity 'IMMUNE RESPONSE' named entity 'CYTOMEGALOVIRUS INFECTION' named entity 'LIKELY' covid:arg/90662d7dc7b09e018829ae2bc13e167b218931d8 named entity 'infectious diseases' named entity 'mAbs' named entity 'immune' named entity 'cytomegalovirus infection' named entity 'cloned' named entity 'ligation' named entity 'IgG' named entity 'variety of diseases' named entity 'HCMV' named entity 'HIV' named entity 'cell lysate' named entity 'CD22' named entity 'HCMV' named entity 'flow cytometer' named entity 'ligand' named entity 'HUVEC' named entity 'clones' named entity 'CD22' named entity 'supernatants' named entity 'primers' named entity 'EBV' named entity 'amino terminus' named entity 'EBV' named entity 'Germany' named entity 'IL-2' named entity 'serum' named entity 'HCMV' named entity 'chromatography' named entity 'HCMV' named entity 'E. coli' named entity 'subclinical disease' named entity 'Antibodies' named entity 'screening assay' named entity 'physiological' named entity 'HCMV' named entity 'viral pathogens' named entity 'cloning' named entity 'recombinant' named entity 'cDNA' named entity 'cell-mediated response' named entity 'infectious diseases' named entity 'immunocompetent' named entity 'FITC' named entity 'lymphocytes' named entity 'EBV infection' named entity 'EBV' named entity 'B-lymphocytes'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software